icon-folder.gif   Conference Reports for NATAP  
 
  EACS - 12th European AIDS Conference
November 11-14, 2009
Cologne, Germany
Back grey_arrow_rt.gif
 
 
 
A Phase II, open-label trial in treatment-na´ve, HIV-1-infected patients who received DRV/r as induction monotherapy
 
 
  Reported by Jules Levin
EACS Nov 13 2009, Cologne, Germany
 
Patricia Patterson,1 Alejandro Krolewiecki,1 Frank Tomaka,2 Sabrina Spinosa-Guzman,3 Diego Miralles4 and Pedro Cahn1
 
1Fundacion Huesped, Buenos Aires, Argentina;
2Tibotec Inc, Yardley, PA, USA; 3Tibotec BVBA, Mechelen, Belgium; 4PRD West Coast Research Center, San Diego, CA, USA
 

image002.gif

image004.gif

image006.gif

image008.gif

1. Squires et al, 5th IAS 2009. Abstract TUAB106-LB; Ripamonti et al, 12th EACS 2009. Abstract PS4/1

image010.gif

image012.gif

*The following polymorphisms were allowed as they have no known effect on DRV susceptibility: I13V, K20I/M/R, M36I/V, D60E, I62V, L63P, A71T/V, V77I and I93L

image014.gif

image016.gif

image018.gif

image020.gif

image022.gif

image024.gif

image026.gif